New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.
Integrated approach reduces harmful effects of medicines in surface waters Residues of medicinal products, such as painkillers, hormones and antidepressants, are increasingly detected in surface water and drinking water.
Lab tests alone not conclusive for diagnosis of Lyme disease Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.
Nanotechnology increasingly used in medical devices The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.
Eating less salt can prevent tens of thousands of heart attacks and strokes Lowering the amount of salt in processed foods or choosing low-salt alternatives can lead to substantial health benefits when it comes to cardiovascular disease.
Major loss of healthy life years due to long-term complaints after Lyme disease The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.
Broad approach needed against pharmaceutical residues in environment We can all help to reduce pollution of the environment by pharmaceutical residues.
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.